NCT04282278

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Hebei Medical University Fourth Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	Camrelizumab/sintilimab+ Standard chemotherapy	Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
DRUG	Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）	Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
DRUG	Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy	Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3

Timeline

• Start date: 2020-07-16
• Primary completion: 2022-04-01
• Completion: 2024-04-01
• First posted: 2020-02-24
• Last updated: 2021-12-10

Locations

1 site across 1 country: China